-
-
Humanized model of the immune system
-
iHuPBMC-T
-
iHuPBMC-NK
-
iHuPBMC-B
-
PBMC-LT
-
CD34+ HSC
-
Winn model
-
iHuPBMC-MHC/KO
-
iHuPBMC-OncVax
-
PBMC mixed inoculation model
more -
-
In vivo tumor experimental platform
-
CDX
-
iHuPDX
-
Non-GLP Toxicology
-
PK/PD
-
Brain in situ model
-
Other in situ models
-
Hematologic tumor model system inoculation
-
Creation of high interstitial tumor models
more -
-
In vitro killing experiment platform
-
Immune co-culture killing model
-
CDC
-
In vitro killing experiment platform
-
IC50
-
PDC High-Throughput In Vitro Pharmacodynamics
-
3D organoids
-
ADCC
-
T cell-mediated killing experiment
more -
-
Mouse-derived immune system model
more -
Tumor vaccine
more -
Cell therapy
more -
In vitro testing platform
more -
Non-GLP Toxicology Platform
more -
Non-tumor model and drug efficacy evaluation platform
-
Systematic Vaccination Model
-
Non-tumor model and drug efficacy evaluation platform
-
Skin injury model
-
Stroke model
-
Liver fibrosis model
-
Diabetes model
-
Gouty Arthritis (GA) Model
-
Pulmonary fibrosis model
-
Systemic lupus erythematosus (SLE) model
-
Inflammatory Bowel Disease (IBD) model
-
Rheumatoid Arthritis (RA) Model
more -
-
-
-
PDX model
-
PDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
CDX model
-
CDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
Homogeneous Model
-
Homogeneous Model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Breast cancer
-
Stomach cancer
-
Liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Pancreatic cancer
-
Kidney cancer
-
Bladder cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer
-
Ovarian cancer
-
Esophageal cancer
-
Skin cancer
-
sarcoma
-
Nervous System Cancer
-
Embryonal carcinoma
-
Lymphoma
-
Leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other
-
Colorectal cancer
more -
-
News Center
——
InnoModels Biotechnology: Immune Co-Culture Killing Models
Author:
InnoModels
Release time:
2024-04-17
With the continuous development of biological science and medical technology, human understanding of diseases and treatment modalities are gradually deepening. Among them, immunotherapy, as an emerging therapeutic modality, has shown great potential in fields such as cancer. However, the mechanism of immunotherapy is complex, and how to accurately simulate the immune response process in the body has been a challenge for researchers. For this reason, InnoModels Biotechnology has developed a new 3D immune co-culture killing model, which aims to more realistically simulate the interaction between immune cells and tumor cells in the body, providing a more accurate tool for immunotherapy research.
1. 3D tissue simulation: restoring the real immune environment
Traditional immune models can only simulate simple cell-cell interactions, but cannot fully restore the complex immune environment in the body. The 3D immune co-culture killing model of InnoModels Biotechnology, however, constructs a more realistic 3D tissue structure through precise cell culture technology, which better simulates the complex interactions between immune cells and tumor cells in vivo. This three-dimensional structure not only provides a closer cell survival environment in vivo, but also simulates the spatial distribution and interaction between cells, making the experimental results more informative.
2、Multi-cell type participation: comprehensive simulation of immune response
Compared with traditional immune models, the 3D immune co-culture killing model of InnoModels Biotechnology is able to introduce a variety of immune cell types at the same time, such as natural killer cells (NK cells), T cells, etc. This involvement of multiple cell types makes it possible to simulate the immune response in a comprehensive way. This involvement of multiple cell types enables the model to simulate more complex immune response processes, and the experimental results are more biologically meaningful. In addition, this visualization also enables researchers to intuitively observe the killing process of immune cells, which helps to gain a deeper understanding of the mechanism of immunotherapy.

3、Application Prospects: Helping Immunotherapy Research
The 3D immune co-culture killing model of InnoModels provides strong support for immunotherapy research. Its accurate simulation of the interaction between immune cells and tumor cells in vivo enables researchers to more accurately predict the effects of therapeutic drugs in vivo. This is of great significance for optimizing treatment plans, improving treatment efficiency and reducing side effects. At the same time, the model also helps researchers gain a deeper understanding of the mechanism of immunotherapy, providing new ideas and methods for future immunotherapy.
In conclusion, the 3D immune co-culture killing model of InnoModels has revolutionized immunotherapy research. Its precise simulation of the in vivo immune environment, participation of multiple cell types, and visualization make immunotherapy research more in-depth and comprehensive. With the continuous development and improvement of this technology, it is believed that future immunotherapy will be more accurate and efficient, bringing hope to more patients.
InnoModels Biotechnology (Beijing) Co., Ltd.
-
TEL: +86 15711355061
-
E-mail: xuyl@imodels.tech
-
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
InnoModels Biotechnology (Beijing) Co., Ltd